Johns Hopkins Prostate Cancer Translational Program
SPORE in Prostate Cancer
['FUNDING_OTHER'] · JOHNS HOPKINS UNIVERSITY · NIH-11180115
This program develops new treatments that target hormone signaling, DNA-repair problems, and immune responses for men with prostate cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11180115 on ClinicalTrials.gov |
What this research studies
This Johns Hopkins program brings scientists and clinicians together to turn lab discoveries about prostate cancer into new treatments for patients. Researchers are focusing on how tumors adapt to hormones, how DNA-repair defects drive cancer, and how the tumor environment blocks immune responses. The program supports clinical trials, biomarker testing, and studies using patient tumor samples to guide targeted therapies. If you join, doctors may use genetic tests and specialized treatments developed through these projects to try to personalize your care.
Who could benefit from this research
Good fit: Men with high-risk, recurrent, or metastatic prostate cancer — especially those with hormone-resistant disease or DNA-repair mutations — are the most likely candidates.
Not a fit: Men with very low-risk prostate cancer who are unlikely to need systemic treatments, or those unable to travel to study sites, may not benefit from these projects.
Why it matters
Potential benefit: Could produce more personalized therapies that extend survival and expand treatment options for men with advanced or treatment-resistant prostate cancer.
How similar studies have performed: Previous trials targeting androgen signaling, DNA-repair defects (for example with PARP inhibitors), and immune approaches have shown some promise but have not yet produced widespread durable cures, and this program builds on those advances.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DENMEADE, SAMUEL R — JOHNS HOPKINS UNIVERSITY
- Study coordinator: DENMEADE, SAMUEL R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Research Programs, Cancer Research Project